Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 2
2021 3
2023 3
2024 6
2025 25
2026 13

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

43 results

Results by year

Filters applied: in the last 5 years. Clear all
Page 1
Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC.
Planchard D, Jänne PA, Cheng Y, Yang JC, Yanagitani N, Kim SW, Sugawara S, Yu Y, Fan Y, Geater SL, Laktionov K, Lee CK, Valdiviezo N, Ahmed S, Maurel JM, Andrasina I, Goldman J, Ghiorghiu D, Rukazenkov Y, Todd A, Kobayashi K; FLAURA2 Investigators. Planchard D, et al. N Engl J Med. 2023 Nov 23;389(21):1935-1948. doi: 10.1056/NEJMoa2306434. Epub 2023 Nov 8. N Engl J Med. 2023. PMID: 37937763 Clinical Trial.
CONCLUSIONS: First-line treatment with osimertinib-chemotherapy led to significantly longer progression-free survival than osimertinib monotherapy among patients with EGFR-mutated advanced NSCLC. (Funded by AstraZeneca; FLAURA2 ClinicalTrials.gov number, NCT04035486.)....
CONCLUSIONS: First-line treatment with osimertinib-chemotherapy led to significantly longer progression-free survival than osimertinib monot …
Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC.
Jänne PA, Planchard D, Kobayashi K, Yang JC, Liu Y, Valdiviezo N, Kim TM, Jiang L, Kagamu H, Yanagitani N, Wang J, Biswas B, Poltoratskiy A, Neron Y, Rojas C, Koubkova L, Escriu C, Ezeife DA, Mann H, Armenteros-Monterroso E, Rukazenkov Y, Lee CK; FLAURA2 Investigators. Jänne PA, et al. N Engl J Med. 2026 Jan 1;394(1):27-38. doi: 10.1056/NEJMoa2510308. Epub 2025 Oct 17. N Engl J Med. 2026. PMID: 41104938 Clinical Trial.
CONCLUSIONS: Among patients with EGFR-mutated advanced NSCLC, first-line treatment with osimertinib plus platinum-pemetrexed led to significantly longer overall survival than osimertinib monotherapy and was associated with an increased risk of reversible adverse events of grade 3 …
CONCLUSIONS: Among patients with EGFR-mutated advanced NSCLC, first-line treatment with osimertinib plus platinum-pemetrexed led to signific …
CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung Cancer.
Jänne PA, Planchard D, Kobayashi K, Cheng Y, Lee CK, Valdiviezo N, Laktionov K, Yang TY, Yu Y, Kato T, Jiang L, Chewaskulyong B, Lucien Geater S, Maurel JM, Rojas C, Takahashi T, Havel L, Shepherd FA, Tanaka K, Ghiorghiu D, Amin NP, Armenteros-Monterroso E, Huang X, Chaudhry AA, Yang JC. Jänne PA, et al. J Clin Oncol. 2024 Mar 1;42(7):808-820. doi: 10.1200/JCO.23.02219. Epub 2023 Dec 2. J Clin Oncol. 2024. PMID: 38042525 Free PMC article. Clinical Trial.
PURPOSE: We report CNS efficacy of first-line osimertinib plus chemotherapy versus osimertinib monotherapy in patients with epidermal growth factor receptor (EGFR)-mutated advanced non-small-cell lung cancer (NSCLC) from the phase III FLAURA2 study according to baseline CN …
PURPOSE: We report CNS efficacy of first-line osimertinib plus chemotherapy versus osimertinib monotherapy in patients with epidermal growth …
Osimertinib plus platinum-pemetrexed in newly diagnosed epidermal growth factor receptor mutation-positive advanced/metastatic non-small-cell lung cancer: safety run-in results from the FLAURA2 study.
Planchard D, Feng PH, Karaseva N, Kim SW, Kim TM, Lee CK, Poltoratskiy A, Yanagitani N, Marshall R, Huang X, Howarth P, Jänne PA, Kobayashi K. Planchard D, et al. ESMO Open. 2021 Oct;6(5):100271. doi: 10.1016/j.esmoop.2021.100271. Epub 2021 Sep 17. ESMO Open. 2021. PMID: 34543864 Free PMC article.
BACKGROUND: The phase III FLAURA2 (NCT04035486) study will evaluate efficacy and safety of first-line osimertinib with platinum-pemetrexed chemotherapy versus osimertinib monotherapy in epidermal growth factor receptor mutation-positive (EGFRm) advanced/metastatic non-smal …
BACKGROUND: The phase III FLAURA2 (NCT04035486) study will evaluate efficacy and safety of first-line osimertinib with platinum-pemet …
Patient-Reported Outcomes in FLAURA2: Osimertinib with or without Chemotherapy in Patients with Previously Untreated EGFR-Mutated Advanced Non-Small Cell Lung Cancer.
Gray JE, Laktionov K, Kim SW, Kato T, Wang J, Han Z, Mitchell P, Kuyama S, Tan Chun Bing J, Cundom J, Pinto G, Shepherd FA, Poole L, Lai R, Albayaty M, Amin NP, Kobayashi K, Lee CK. Gray JE, et al. Clin Cancer Res. 2026 Jun 1;32(11):2144-2156. doi: 10.1158/1078-0432.CCR-25-3431. Clin Cancer Res. 2026. PMID: 41801128 Free PMC article. Clinical Trial.
PURPOSE: In FLAURA2, first-line osimertinib plus platinum-pemetrexed induction, with osimertinib plus pemetrexed maintenance, improved progression-free survival versus osimertinib alone in epidermal growth factor receptor (EGFR)-mutated, advanced non-small cell lung cancer …
PURPOSE: In FLAURA2, first-line osimertinib plus platinum-pemetrexed induction, with osimertinib plus pemetrexed maintenance, improve …
First-line treatment in EGFR-mutated non-small cell lung cancer: brief report of an individual patient data comparison of phase 3 clinical trials.
Torchia A, Sabatini A, Bengala E, Di Civita MA, Ciurluini F, Marinelli D, Giammaruco M, Laudisi A, Gelibter A, Minuti G, Landi L, Santini D, Cappuzzo F. Torchia A, et al. Lung Cancer. 2025 Dec;210:108845. doi: 10.1016/j.lungcan.2025.108845. Epub 2025 Nov 19. Lung Cancer. 2025. PMID: 41270639 Free article.
FLAURA2 PFS was longer in patients with central nervous system (CNS) metastases (HR 0.63), without liver metastases (HR 0.73), and with EGFR L858R (HR 0.68). ...No new safety signals resulted from the safety analysis. In FLAURA2, anemia, diarrhea, and neutropenia we …
FLAURA2 PFS was longer in patients with central nervous system (CNS) metastases (HR 0.63), without liver metastases (HR 0.73), and wi …
Cost-effectiveness analysis of osimertinib plus chemotherapy for patients with EGFR-mutated advanced non-small cell lung cancer.
Tian W, Niu L, Zhou R, Wang Z, Ning J, Lu R, Shi Y, Tan Z. Tian W, et al. Cancer Med. 2024 Aug;13(16):e70083. doi: 10.1002/cam4.70083. Cancer Med. 2024. PMID: 39206619 Free PMC article.
INTRODUCTION: First-line osimertinib plus chemotherapy significantly prolonged progression-free survival of patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) compared to osimertinib, according to the FLAURA2 trial. METHODS: We established a Markov mode …
INTRODUCTION: First-line osimertinib plus chemotherapy significantly prolonged progression-free survival of patients with EGFR-mutated advan …
Population Pharmacokinetics and Exposure-Response Analysis of First-Line Osimertinib Plus Chemotherapy in Patients with EGFR-Mutated Advanced NSCLC.
Yang J, Olabode D, Sawant-Basak A, Baldry R, Vishwanathan K, Bachina S, Todd A, Ghiorghiu D, Rukazenkov Y, Zhou D, Shahraz A. Yang J, et al. Clin Pharmacol Ther. 2025 Nov;118(5):1110-1121. doi: 10.1002/cpt.3759. Epub 2025 Jul 10. Clin Pharmacol Ther. 2025. PMID: 40637621 Free PMC article. Clinical Trial.
A population pharmacokinetics analysis using cumulative pharmacokinetics data from 2,196 patients across six studies (AURA, AURA2, AURA3, ADAURA, FLAURA, and FLAURA2) assessed pharmacokinetics and its variability due to intrinsic and extrinsic factors. ...These results fur …
A population pharmacokinetics analysis using cumulative pharmacokinetics data from 2,196 patients across six studies (AURA, AURA2, AURA3, AD …
43 results